Treatment with ICIs, which are directed against the immune checkpoint programmed cell death ligand 1 (PD-L1), demonstrated a marked OS improvement in patients with melanoma and non-small cell lung cancer (NSCLC) as well as other entities [8–11]. Here, CD274 is linked to non-small cell lung carcinoma.